関連する実験動画
Updated: Sep 9, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.0K
[レスベラトロールの抗血栓作用:特に血小板結束の抑制に関する]
Kazumi Ekawa1, Mikio Marumo1, Ichiro Wakabayashi1
1Department of Preventive Medicine, Faculty of Medicine, Hyogo Medical University.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
|August 31, 2025
まとめ
レッドワインに含まれるレスベラトロールとエタノールは,動脈硬化症の重要な要因である血小板の集積を防止する添加効果を示します. この化合物は,心血管疾患に対する複数の保護作用を提供します.
科学分野:
- 心血管科学
- 薬理学について
- 栄養薬
背景:
- 発血性心臓病の予防は 適度な赤ワインの摂取と関連しています これは"フランスのパラドックス"として知られています
- レッドワインには,レスベラトロールやエタノールなどのポリフェノールがあり,心臓保護効果に貢献する可能性があります.
- 血小板は動脈硬化と血栓形成に 重要な役割を果たします
研究 の 目的:
- レズベラトロールとエタノールの血小板集積に対する影響を調査する.
- レスベラトロールが血小板機能を抑制するメカニズムを解明する.
- レスベラトロールが動脈硬化と血栓形成を予防する可能性を評価する.
主な方法:
- レズベラトロールが血小板Ca2+の流入と集積に及ぼす影響を調べたインビトロ試験.
- レスベラトロールとエタノールとの併用試験で,併用効果を評価した.
- レスベラトロールの抗酸化作用と血小板信号伝達経路への影響の分析
主要な成果:
- レスベラトロールは血小板の集積とCa2+の流れを濃度に依存して抑制した.
- レスベラトロールとエタノールは,血小板の集積に対する追加的抑制効果を示した.
- レスベラトロールのメカニズムは,抗酸化作用,容量Ca2+流入の抑制,およびサイクロオキシゲネーゼ1およびフォスフォリファーゼA2の直接的抑制を含む.
結論:
- レスベラトロールは複数の抗動脈硬化および抗血栓性を持っています.
- レスベラトロールは,エタノールと併用して,血小板の集積を抑制します.
- レスベラトロールの多面的な作用は,心臓血管疾患の治療薬としての可能性を示唆しています.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
01:22Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33